Ocugen falls after interim trial data disappoints
Ocugen fell nearly 14% after a disappointing interim analysis from a Phase 2/3 trial for OCU410ST, its experimental therapy for Stargardt disease.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.